Mather Group LLC. Has $4.32 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Mather Group LLC. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,402 shares of the company’s stock after selling 280 shares during the quarter. Mather Group LLC.’s holdings in Eli Lilly and Company were worth $4,315,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. PDS Planning Inc increased its holdings in shares of Eli Lilly and Company by 1.7% in the 3rd quarter. PDS Planning Inc now owns 4,975 shares of the company’s stock valued at $2,672,000 after purchasing an additional 83 shares during the period. Boyd Watterson Asset Management LLC OH increased its stake in Eli Lilly and Company by 1.5% in the 3rd quarter. Boyd Watterson Asset Management LLC OH now owns 12,141 shares of the company’s stock valued at $6,521,000 after buying an additional 180 shares during the period. Cavalier Investments LLC lifted its position in Eli Lilly and Company by 67.8% in the 3rd quarter. Cavalier Investments LLC now owns 3,881 shares of the company’s stock worth $2,085,000 after buying an additional 1,568 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Eli Lilly and Company by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 337,104 shares of the company’s stock valued at $181,069,000 after buying an additional 7,254 shares during the period. Finally, LFA Lugano Financial Advisors SA purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $60,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LLY. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, Citigroup raised their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $737.33 on Tuesday. The company has a market cap of $700.58 billion, a price-to-earnings ratio of 127.13, a PEG ratio of 1.60 and a beta of 0.34. The business has a 50 day moving average price of $760.89 and a 200 day moving average price of $668.00. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.09 earnings per share. Research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.